News Quantified


All News	{{AllNewsCount}}
News Wires	{{NewsWiresCount}}
Media Monitoring	{{MoreOverCount}}
SEC Edgar Filings	{{SecEdgarFilingsCount}}
Upgrades	{{UpgradesCount}}
Downgrades	{{DowngradesCount}}
Initiated	{{InitiatesCount}}
Reiterated	{{ReiteratesCount}}
Last Earnings	{{LastEarnings}}
Last Earnings EPS	{{LastEps}}
Next Earnings	{{NextEarnings}}

Sub-Penny
{{SubPennyStr}}
Odd Lot
{{OddLotStr}}
Avg. bid-ask spread

{{GetAvgBidAskSpreadForScale}}
Avg. bid / ask size
{{GetAvgBidSizeForScale}} {{GetAvgAskSizeForScale}}

Shares at ask / bid
{{SharesAtAsk_AMP_Str}} {{SharesAtBid_AMP_Str}}
Off exchange
{{OffExchange}}

News

Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings

Lumos Pharma, Inc. (NASDAQ: LUMO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $28.00 price target on the stock.

Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042 [Yahoo! Finance]

Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042

Lumos Pharma Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]

8/9/2023

04:01 pm

lumo

-5.8%

MISS

5/3/2023

04:05 pm

lumo

9.1%

BEAT

Form 10-K/A LUMOS PHARMA, INC. For: Dec 31

Form 8-K LUMOS PHARMA, INC. For: Apr 18

Form ARS LUMOS PHARMA, INC. For: Dec 31

Form DEFA14A LUMOS PHARMA, INC.

Form DEF 14A LUMOS PHARMA, INC. For: Dec 31

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}